What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"
Xiaobin Wu, insider at BeiGene

Xiaobin Wu Insider Information

COO of BeiGene
Xiaobin Wu, Ph.D., joined BeiGene in 2018 and currently serves as President, Chief Operating Officer, and General Manager of China. Dr. Wu was previously the Country Manager of Pfizer China and the Regional President of Pfizer Essential Health for Greater China from October 2009 to April 2018. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, grew sales meaningfully, initiated a range of innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from August 2004 to October 2009. Before Wyeth, Dr. Wu was General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany. Dr. Wu received a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany.

What is Xiaobin Wu's net worth?

The estimated net worth of Xiaobin Wu is at least $163,468.50 as of June 17th, 2022. Dr. Wu owns 1,010 shares of BeiGene stock worth more than $163,469 as of June 30th. This net worth evaluation does not reflect any other investments that Dr. Wu may own. Additionally, Dr. Wu receives a salary of $1,640,000.00 as COO at BeiGene. Learn More about Xiaobin Wu's net worth.

How old is Xiaobin Wu?

Dr. Wu is currently 60 years old. There are 5 older executives and no younger executives at BeiGene. Learn More on Xiaobin Wu's age.

What is Xiaobin Wu's salary?

As the COO of BeiGene, Ltd., Dr. Wu earned a total compensation package of $8,425,344.00 in 2020. Dr. Wu earned a salary of $606,896.00, stock awards of $1,799,943.00, options awards of $5,399,994.00, non-equity compensation of $435,853.00, and other compensation of $182,658.00.The highest earning executive at BeiGene is Mr. John V. Oyler, Co-Founder, Exec. Chairman & CEO, who commands a salary of $1,750,000.00 per year. Learn More on Xiaobin Wu's salary.

How do I contact Xiaobin Wu?

The corporate mailing address for Dr. Wu and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at 861085148500 and via email at [email protected] Learn More on Xiaobin Wu's contact information.

Has Xiaobin Wu been buying or selling shares of BeiGene?

In the last ninety days, Xiaobin Wu has sold $1,815,932.05 in shares of BeiGene stock. Most recently, 0 shares of the business's stock in a transaction dated Thursday, June 30th. Learn More on Xiaobin Wu's trading history.

Who are BeiGene's active insiders?

BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Howard Liang (CFO), John Oyler (CEO), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.

Are insiders buying or selling shares of BeiGene?

During the last twelve months, BeiGene insiders bought shares 2 times. They purchased a total of 2,709,329 shares worth more than $57,249,519.74. During the last twelve months, insiders at the sold shares 26 times. They sold a total of 595,765 shares worth more than $83,363,999.02. The most recent insider tranaction occured on June, 27th when insider Lai Wang sold 458 shares worth more than $81,212.56. Insiders at BeiGene own 8.9 % of the company. Learn More about insider trades at BeiGene.

Information on this page was last updated on 6/27/2022.

Xiaobin Wu Insider Trading History at BeiGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2022Sell1,010$144.36$145,803.60View SEC Filing Icon  
6/17/2022Sell578$139.60$80,688.801,010View SEC Filing Icon  
6/6/2022Sell3,410$141.99$484,185.90View SEC Filing Icon  
5/5/2022Sell6,725$164.35$1,105,253.75View SEC Filing Icon  
7/6/2021Sell10,180$325.53$3,313,895.401,081,389View SEC Filing Icon  
6/18/2021Sell1,156$330.93$382,555.08
6/7/2021Sell3,398$352.54$1,197,930.921,150,757View SEC Filing Icon  
5/3/2021Sell6,715$343.00$2,303,245.00View SEC Filing Icon  
7/20/2020Sell3,300$249.22$822,426.001,423,562View SEC Filing Icon  
7/17/2020Sell700$245.74$172,018.001,423,562View SEC Filing Icon  
7/15/2020Sell2,700$241.11$650,997.001,466,462View SEC Filing Icon  
7/13/2020Sell3,000$220.00$660,000.001,466,462View SEC Filing Icon  
6/8/2020Sell2,800$170.83$478,324.001,380,415View SEC Filing Icon  
5/1/2020Sell7,024$141.33$992,701.92View SEC Filing Icon  
5/1/2019Sell5,955$124.52$741,516.60View SEC Filing Icon  
See Full Table

Xiaobin Wu Buying and Selling Activity at BeiGene

This chart shows Xiaobin Wu's buying and selling at BeiGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BeiGene Company Overview

BeiGene logo
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $161.85
Low: $154.80
High: $162.60

50 Day Range

MA: $145.63
Low: $121.11
High: $177.99

2 Week Range

Now: $161.85
Low: $118.18
High: $426.56

Volume

296,269 shs

Average Volume

314,842 shs

Market Capitalization

$16.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.